Factors associated to persistence on Golimumab in patients with inflammatory arthritis of the BIOBADASER registry
14/08/2023
M.V. Hernández1 , S. Rodriguez1 , R. Morlà1 , C. Sánchez-Piedra2 , F. SánchezAlonso2 , F.J. Manero3 , B. García-Magallón4 , E. Pérez-Pampín5 , C. RodríguezLozano6 , M.D. Ruiz7 , A. Ortiz8 , C. Díaz-Torné9 , L. Mateo10, J.A. Gómez-Puerta1 , R. Sanmartí1 , L. Cea-Calvo11, J.J. Gómez-Reino5 , on behalf of BIOBADASER Study Group
EULAR 2018
DOI: 10.1136/annrheumdis-2018-eular.4577
https://ard.bmj.com/content/77/Suppl_2/1755.3